Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Prescription Drugs

Reports

Displaying 1 - 10 of 57. 10 per page. Page 1.

Advanced Search
ASPE Issue Brief

Trends in Prescription Drug Spending, 2016-2021

September 30, 2022
High prescription drug costs are a leading concern among Americans. Americans pay higher prices for prescription drugs than any other country in the world, with prescription drug prices in the U.S. more than 2.5 times as high as those in other similar high-income nations.

Price Increases for Prescription Drugs, 2016-2022

September 30, 2022
Prescription drug price increases create affordability challenges for patients and for the government. This report tracks drug price changes from 2016-2022. There were 1,216 products whose price increases during the twelve-month period from July 2021 to July 2022 exceeded the inflation rate of 8.5 percent for that time period. The average price increase for these drugs was 31.6 percent.
Report

International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies

July 1, 2022
Key Findings Policy discussion surrounding U.S. prescription drug prices focuses on whether prices in the United States are too high or appropriate relative to the benefits that they offer to patients.
ASPE Issue Brief

Antipsychotic Medication Prescribing in Long Term Care Facilities Increased in the Early Months of the COVID-19 Pandemic Issue Brief

April 7, 2022
Prescriptions dispensed for antipsychotics in nursing homes and assisted living facilities increased since the beginning of the pandemic, with 20.8 thousand dispensed in 2020 compared to 20.5 thousand in 2019. This represents a 1.5% increase in total prescriptions since the beginning of the pandemic despite lower resident census levels in long-term care facilities (LTCFs).
Report

Cost of Generic Drug Development and Approval

February 3, 2022
The purpose of this study was to estimate the cost of generic drug development and approval. This study develops an analytical framework for examining the expected net present value (ENPV) (i.e., the difference between the present value of expected revenues over product life and cost of product development and approval) to a generic drug developer in different size drug markets.
ASPE Data Point

Prescription Drug Affordability among Medicare Beneficiaries

January 19, 2022
More than 5 million Medicare beneficiaries struggle to afford prescription medications. Among adults 65 and older, Black and Latino beneficiaries are most likely to experience affordability problems. Medicare beneficiaries with lower incomes and those under age 65 also had above-average rates of not taking needed medications due to cost.
Report

Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships

October 14, 2021
Many stakeholders and steps are involved in the life cycle of a prescription drug as it moves from chemical synthesis and formulation through dispensing or administration to patients. The specific steps involved in prescription drug supply chains often differ depending on the type of drug, the channel of distribution, and the patient’s source of prescription drug coverage.
Report

Assessing Relationships between Drug Shortages in the United States and Other Countries

October 13, 2021
Drug shortages are a persistent public health problem in the United States and in other countries. Shortages can have important implications for the health care systems and pharmacies that purchase, store, and dispense drugs and for the patients who rely on the availability of drugs to treat and prevent disease.
Report

Comprehensive Plan for Addressing High Drug Prices: A Report in Response to the Executive Order on Competition in the American Economy

September 9, 2021
President Biden’s Executive Order 14036, “Promoting Competition in the American Economy” (the Competition Executive Order), identifies a lack of competition as a key driver for problems across economic sectors.

Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey

May 17, 2021
This study presents the findings of a national survey of physicians about their knowledge of biosimilar biological products as well as the impact of biological product naming conventions on prescriber choice. Related Products